The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Nicola Normanno

Cell Biology and Biotherapy Unit

INT Fondazione G. Pascale

Naples

Italy

[email]@yahoo.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Cell Biology and Biotherapy Unit, INT Fondazione G. Pascale, Naples, Italy. 2001 - 2011
  • Division of Hematological Oncology and Department of Experimental Oncology, INT-Fondazione Pascale, 80131 Naples, Italy. 2003 - 2004

References

  1. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. Normanno, N., Pinto, C., Castiglione, F., Bardelli, A., Gambacorta, M., Botti, G., Nappi, O., Siena, S., Ciardiello, F., Taddei, G., Marchetti, A. PLoS. ONE (2011) [Pubmed]
  2. Re: biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Normanno, N., Tejpar, S., Ciardiello, F. J. Natl. Cancer Inst. (2010) [Pubmed]
  3. Target-based therapies in breast cancer: current status and future perspectives. Normanno, N., Morabito, A., De Luca, A., Piccirillo, M.C., Gallo, M., Maiello, M.R., Perrone, F. Endocr. Relat. Cancer (2009) [Pubmed]
  4. Prognostic applications of gene expression signatures in breast cancer. Normanno, N., De Luca, A., Carotenuto, P., Lamura, L., Oliva, I., D'Alessio, A. Oncology (2009) [Pubmed]
  5. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Normanno, N., Campiglio, M., Maiello, M.R., De Luca, A., Mancino, M., Gallo, M., D'Alessio, A., Menard, S. Breast Cancer Res. Treat. (2008) [Pubmed]
  6. Epidermal growth factor receptor (EGFR) signaling in cancer. Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F., Salomon, D.S. Gene (2006) [Pubmed]
  7. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?. Normanno, N., Gullick, W.J. Endocr. Relat. Cancer (2006) [Pubmed]
  8. The ErbB receptors and their ligands in cancer: an overview. Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., De Luca, A., Caponigro, F., Salomon, D.S. Curr. Drug. Targets (2005) [Pubmed]
  9. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Normanno, N., De Luca, A., Aldinucci, D., Maiello, M.R., Mancino, M., D'Antonio, A., De Filippi, R., Pinto, A. Endocr. Relat. Cancer (2005) [Pubmed]
  10. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. Normanno, N., De Luca, A., Maiello, M.R., Mancino, M., D'Antonio, A., Macaluso, M., Caponigro, F., Giordano, A. Front. Biosci. (2005) [Pubmed]
  11. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F. Endocr. Relat. Cancer (2005) [Pubmed]
  12. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. Normanno, N., De Luca, A., Bianco, C., Maiello, M.R., Carriero, M.V., Rehman, A., Wechselberger, C., Arra, C., Strizzi, L., Sanicola, M., Salomon, D.S. J. Cell. Physiol. (2004) [Pubmed]
  13. CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. Normanno, N., De Luca, A., Maiello, M.R., Bianco, C., Mancino, M., Strizzi, L., Arra, C., Ciardiello, F., Agrawal, S., Salomon, D.S. Int. J. Oncol. (2004) [Pubmed]
  14. Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. Normanno, N., Maiello, M.R., Mancino, M., De Luca, A. J. Chemother (2004) [Pubmed]
  15. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?. Normanno, N., Maiello, M.R., De Luca, A. J. Cell. Physiol. (2003) [Pubmed]
  16. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Normanno, N., Bianco, C., De Luca, A., Maiello, M.R., Salomon, D.S. Endocr. Relat. Cancer (2003) [Pubmed]
  17. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Normanno, N., Campiglio, M., De, L.A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D.S., Menard, S. Ann. Oncol. (2002) [Pubmed]
  18. The role of EGF-related peptides in tumor growth. Normanno, N., Bianco, C., De Luca, A., Salomon, D.S. Front. Biosci. (2001) [Pubmed]
 
WikiGenes - Universities